HPV vaccine awareness, perceptions, uptake, and school-based information channels during Nigeria’s national rollout: a cross-sectional study among adolescent girls in rural Oyo State Authors: Ifeoluwa Eunice Adewole, Folahanmi Tomiwa Akinsolu, Olunike Rebecca Abodunrin, Akim Tafadzwa Lukwa, Oluwabukola Mary Ola, Gift Modupe Adelaja, Mobolaji Timothy Olagunju, Abel Nnamdi Chukwuemeka, Lilian Ogochukwu Ezechi, Dolapo Omotayo Raji, Posi Emmanuel Aduroja, Oliver Chukwujekwu Ezechi Published: 2026 ABSTRACT AbstractBackgroundNigeria introduced the human papillomavirus (HPV) vaccine into its national routine immunisation programme in October 2023, using a phased delivery strategy that included school- and community-based platforms. Evidence remains limited on how adolescent girls in rural communities understand HPV vaccination during active rollout. This study assessed awareness, knowledge, perceptions, self-reported HPV vaccine uptake, and willingness to receive the vaccine among adolescent girls in rural Oyo State during the Phase-2 national rollout.MethodsWe conducted a school-based cross-sectional survey among 441 in-school adolescent girls recruited from 12 public and private secondary schools across three rural local government areas of Oyo State between 26 May and 19 June 2024. Structured questionnaires measured knowledge of cervical cancer, HPV, and HPV vaccination, as well as perceptions, beliefs, and self-reported vaccination status. Multivariable binary logistic regression was used to identify factors associated with HPV vaccine uptake and willingness to be vaccinated.ResultsAwareness of cervical cancer (26.1%), HPV (28.8%), and HPV vaccination (29.0%) was low. Schools were the most frequently reported source of information on cervical cancer and HPV among those who had heard of them. Forty-one participants (9.3%) self-reported having received the HPV vaccine. In adjusted analysis, favourable vaccine perception was strongly associated with self-reported uptake (AOR = 11.00; 95% CI: 3.53–34.25; p < 0.001), although this estimate should be interpreted cautiously because the vaccinated subgroup was small. Among unvaccinated participants, lack of information (49.3%), low perceived risk (20.3%), and concerns about side effects (16.0%) were the most frequently reported reasons for non-vaccination. Definite willingness to be vaccinated was associated with favourable vaccine perception (AOR = 6.24; 95% CI: 3.16–12.33; p < 0.001).ConclusionsDuring Nigeria’s HPV vaccine rollout, self-reported uptake among adolescent girls in rural Oyo State was low and was associated more consistently with favourable vaccine perceptions than with knowledge measures alone. The findings suggest the potential value of strengthening school-based communication, providing adolescent-appropriate information, and considering parent/guardian engagement as part of rural HPV vaccination implementation. Because the study was cross-sectional and vaccination status was primarily self-reported, findings should be interpreted as associations rather than causal effects.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s12889-026-28335-8.Keywords: School-based vaccination, Rural health, Vaccine acceptance, Adolescent girls, Human papillomavirus, Cervical Cancer Introduction Cervical cancer remains one of the most preventable yet deadly cancers affecting women globally. Persistent infection with high-risk human papillomavirus (HPV), typically acquired through sexual contact, is the cause of nearly all cervical cancers [1, 2]. Despite the availability of highly effective prophylactic vaccines and reliable early detection methods, the global burden remains substantial, with an estimated 604,000 new cases and 342,000 deaths recorded in 2020, making cervical cancer the fourth most common cancer among women worldwide [3, 4]. Beyond mortality, the disease imposes long-term morbidity, high treatment costs, and major productivity losses during women’s most economically productive years, underscoring the urgent need for scalable and equitable prevention strategies [5, 6]. The burden of cervical cancer is profoundly inequitable, reflecting persistent global health disparities. Low- and middle-income countries (LMICs) account for more than 85% of global cervical cancer deaths [7], with sub-Saharan Africa bearing some of the highest incidence and mortality rates worldwide [8]. Within this region, Nigeria faces a severe public health challenge, with approximately 12,000 new cases and over 8,000 deaths reported annually [9]. This disproportionate burden is driven by critically low screening coverage, late presentation, weak health-system capacity, and historically poor HPV vaccine uptake [9]. In response, the World Health Organization (WHO) launched a global strategy to eliminate cervical cancer as a public health problem, setting ambitious 90-70-90 targets to be achieved by 2030: 90% of girls fully vaccinated against HPV by age 15, 70% of women screened with a high-performance test at ages 35 and 45, and 90% of women with cervical disease receiving appropriate treatment [10, 11]. In line with these global goals and recognising the programmatic advantages of a single-dose schedule, Nigeria officially integrated the HPV vaccine into its routine immunisation programme in October 2023 [11]. This policy shift, supported by Gavi, the Vaccine Alliance, and development partners, marked a major step toward strengthening primary prevention of cervical cancer. The national rollout adopted a phased delivery strategy combining facility-based routine immunisation with community- and school-based mass vaccination campaigns. This study was conducted in Oyo State during the Phase-2 rollout period in May 2024, when community sensitisation and mobilisation activities were underway or nearing completion, and vaccine delivery was being expanded to additional schools and communities. This period provided a critical opportunity to assess how rural adolescents understood and perceived HPV, cervical cancer, and the newly introduced vaccine under real-world implementation conditions. Despite this large-scale national effort, achieving high, equitable coverage remains challenging, particularly in rural and hard-to-reach areas. Implementation is constrained by logistical limitations, financial barriers, socio-cultural beliefs, and variable access to accurate information [9, 12]. A growing body of evidence demonstrates that knowledge, attitudes, and perceptions (KAP) play a central role in HPV vaccine acceptance and uptake [13]. However, most Nigerian KAP studies have focused on urban populations, university students, parents or healthcare workers [14–16], leaving limited evidence on the experiences of adolescent girls in rural school settings. These girls may have restricted access to accurate health information, and their vaccination decisions commonly occur within family, school, and community contexts [12, 17]. In such contexts, vaccine acceptance is influenced not only by individual awareness but also by family decision-making, school-based communication, trusted messengers, and perceived risk [18]. To address this evidence gap, this study assessed awareness, knowledge, perceptions, self-reported uptake, and willingness to receive HPV vaccination among adolescent girls in rural Oyo State during Nigeria’s Phase-2 national rollout. Specifically, we aimed to: (1) describe awareness and knowledge of cervical cancer, HPV, and HPV vaccination; (2) assess vaccine-related perceptions, self-reported uptake, and willingness to be vaccinated among unvaccinated girls; and (3) examine factors associated with self-reported HPV vaccine uptake and willingness to receive the vaccine. The study was therefore both descriptive and analytical, aiming to generate implementation-relevant evidence to strengthen school-based HPV vaccination communication in rural settings. Methodology Study design We conducted a school-based cross-sectional survey using quantitative methods to assess awareness, knowledge, perceptions, self-reported HPV vaccine uptake, and willingness to receive HPV vaccination among in-school adolescent girls in rural Oyo State, Nigeria [19]. The study was conducted during Nigeria’s Phase-2 HPV vaccine rollout and captured responses at a single time point; therefore, all associations should be interpreted as non-causal [20, 21]. Study setting and LGA selection The study was conducted in three rural local government areas (LGAs) of Oyo State: Oyo East, Ogbomosho North, and Ibarapa East. These LGAs were purposively selected because they were rural LGAs where school-based HPV vaccination sensitisation and implementation activities were occurring during the Phase-2 rollout period, and because they provided geographic spread across different parts of the state [21, 22]. This purposive selection supported real-time implementation assessment but limits statistical generalisability to all rural LGAs in Oyo State or Nigeria [11]. Study population The study population comprised in-school adolescent girls enrolled in public and private secondary schools in the selected rural LGAs of Oyo State, Nigeria. The study primarily targeted girls aged 9 to 14 years, corresponding to the nationally recommended target population for the single-dose HPV vaccination under Nigeria’s routine immunisation schedule [11]. Focusing on in-school adolescents was appropriate because the national HPV vaccination strategy relies heavily on school-based platforms for vaccine delivery and community sensitisation in rural settings [23]. Eligible participants were primarily girls aged 9–14 years who were registered students in any of the selected schools and whose parents or legal guardians provided written informed consent for their participation [24]. Girls younger than 9 years or those without parental/guardian consent or student assent were excluded. Although the intended eligibility range was 9–14 years, a small number of older students aged 15–16 years who were enrolled in the selected classes and had appropriate consent and assent were retained in the analysis because they participated during field implementation. This group represented 1.6% of the final sample and is reported transparently in the Results Section [24]. Sampling technique A multistage sampling approach was used to select study participants in order to obtain a representative sample of school-going adolescent girls in rural Oyo State [25, 26]. In the first stage, rural LGAs were purposively selected. In the second stage, secondary schools within each selected LGA were chosen using simple random sampling. In the final stage, classes within the selected schools were randomly selected, and all eligible girls within those classes were invited to participate. This approach ensured systematic coverage across multiple schools and communities while minimising selection bias [25, 26]. A total of 12 secondary schools (four per LGA) were selected by simple random sampling from official school lists provided by the Local Education Authorities. In each school, two classes containing students within the target age range were randomly selected. All eligible girls in the selected classes with parent/guardian consent and student assent were invited to participate. The number of participants recruited per school ranged from 30 to 40 students, depending on class size and consent availability, supporting proportional representation across LGAs and schools. Sample size determination and design effect The minimum sample size was calculated using the standard formula for estimating a single population proportion in cross-sectional studies [27]: Where n is the required sample size, Z is the standard normal deviate corresponding to a 95% confidence level (1.96), p is the expected proportion of adequate HPV-related knowledge or vaccine acceptance, and d is the margin of error set at 0.05. Because there was no reliable prior estimate of HPV vaccine awareness or uptake among rural adolescent girls in Oyo State, a conservative prevalence of 50% (p = 0.5) was assumed to maximise sample size and statistical power [28]. This yielded 384 participants. A design effect of 1.1 was applied to account for clustering within schools, corresponding to an assumed low intra-cluster correlation for individual knowledge and perception outcomes across 12 schools. After adding 5% for non-response or incomplete questionnaires, the final target sample was approximately 440 participants. A modest design effect is acknowledged as a limitation, and possible residual school-level clustering was considered when interpreting the regression estimates. Data collection instruments Data were collected using a structured, pre-tested, self-administered questionnaire developed to assess knowledge, perceptions, and acceptance of cervical cancer, HPV, and HPV vaccination among adolescent girls. The instrument was adapted from previously validated HPV knowledge and vaccine acceptance tools used in Nigeria and West Africa [29, 30]. It was contextually modified to reflect Nigeria’s national HPV vaccination programme and the target age group of girls aged 9–14 years. The questionnaire was organised into five sessions: sociodemographic characteristics, knowledge of cervical cancer, knowledge of HPV, knowledge of HPV vaccination, and perceptions and acceptance of HPV vaccination. The full questionnaire is provided as Supplementary File 1. Section A: sociodemographic characteristics This section collected background information on participants, including age, school class/grade, religion, ethnicity, household living arrangement, parental occupation, and estimated daily allowance. These variables were included because they may influence exposure to health information, access to school-based vaccination activities, and health-related decision-making. Relevant sociodemographic variables were also considered as covariates in the regression models. Section B: knowledge of cervical cancer This section assessed participants’ awareness and understanding of cervical cancer, including whether they had ever heard of cervical cancer, sources of information, perceived causes, recognition of early signs and symptoms, knowledge of preventability, awareness of screening, and understanding of selected risk factors such as HPV infection and tobacco use. Knowledge items were scored using a binary approach. Correct responses were assigned a score of 1, while incorrect, “No,” and “Not sure” responses were assigned a score of 0. For multiple-response items, each correct option selected was scored separately. Item scores were summed to generate a composite cervical cancer knowledge score. To aid interpretation, the total score was converted to a percentage. Participants who scored less than 50% were classified as having poor knowledge. In comparison, those who scored 50% or higher were classified as having good knowledge. This cut-off was applied consistently across the knowledge domains. Section C: knowledge of HPV This section evaluated participants’ awareness of HPV, sources of HPV-related information, knowledge of HPV-related health outcomes, routes of transmission, vaccine availability, and interest in learning more about HPV. Multiple-response items captured recognition of cervical cancer, genital warts, and other HPV-related conditions, as well as sexual and skin-to-skin genital contact as possible transmission pathways. Responses were coded using the same binary scoring approach: correct responses were coded as 1, and incorrect or uncertain responses were coded as 0. Scores were summed and converted into percentage scores. Participants scoring less than 50% were categorised as having poor HPV knowledge, while those scoring 50% or higher were categorised as having good HPV knowledge. Because some detailed HPV knowledge questions were asked only among participants who had heard of HPV, denominators were clearly specified in the results tables. This distinction was important to differentiate overall low HPV awareness in the full sample from knowledge levels among the subgroup already aware of HPV. Section D: knowledge of HPV vaccination This section assessed participants’ knowledge of HPV vaccination, including awareness of the HPV vaccine, vaccine-preventable HPV types, recommended age for vaccination, possible side effects, and whether HPV infection may still occur after vaccination. These items were selected to capture factual knowledge relevant to Nigeria’s HPV vaccination programme. Correct responses were assigned a score of 1, while incorrect and “I don’t know” responses were assigned a score of 0. Scores were summed and converted into percentage scores. Participants with scores below 50% were classified as having poor HPV vaccination knowledge, while those with scores of 50% or higher were classified as having good HPV vaccination knowledge. Section E: perceptions and acceptance of HPV vaccination This section measured HPV vaccination status, willingness to receive the HPV vaccine, and perceptions related to vaccine necessity, safety, effectiveness, accessibility, and acceptability. It also assessed motivations for vaccination among vaccinated participants and reasons for non-vaccination among those who had not received the vaccine. HPV vaccination status was assessed by asking participants whether they had received at least one dose of the HPV vaccine. Willingness to receive the HPV vaccine was assessed only among participants who reported not yet being vaccinated. Responses to the willingness question were recorded as “Yes,” “No,” or “Maybe, I need more information.” For regression analysis, willingness was dichotomised. Participants who responded “Yes” were classified as willing to be vaccinated, while those who responded “No” or “Maybe” were classified as not currently willing, because “Maybe” indicated uncertainty or conditional acceptance rather than definite willingness. Perception items assessed beliefs about vaccine necessity, safety, effectiveness, perceived susceptibility, mandatory vaccination, access, and information-related concerns. Responses were coded so that higher scores reflected more favourable perceptions of HPV vaccination. Negatively framed items were reverse-coded where appropriate. A composite perception score was generated by summing the coded responses and converting the total to a percentage. Participants who scored less than 50% were classified as having poor perception, while those who scored 50% or higher were classified as having good perception of HPV vaccination. Scale reliability and validation The questionnaire was reviewed by public health researchers with experience in adolescent health, HPV vaccination, and school-based research to ensure content validity and contextual relevance. It was then pre-tested among adolescent girls at a rural school not included in the final study sample. Feedback from the pre-test was used to improve clarity, age-appropriate comprehension, wording, and cultural suitability before field deployment. Internal consistency of the perception scale was assessed using Cronbach’s alpha. The scale demonstrated good internal consistency, with Cronbach’s alpha = 0.85, indicating that the items used to measure vaccine-related perceptions were sufficiently coherent to serve as a composite measure [31]. The questionnaire was pre-tested among adolescent girls in a non-study rural school to ensure clarity, cultural appropriateness, and age-appropriate comprehension before field deployment [32]. Data collection Data were collected in school settings between 26 May and 19 June 2024, during the Phase-2 rollout of Nigeria’s national HPV vaccination programme [11]. Before fieldwork commenced, ethical approval was obtained. Written informed consent was obtained from parents or legal guardians through consent forms distributed via the participating schools, and assent was obtained from all eligible students before questionnaire administration. On scheduled data collection days, trained research assistants visited each selected school. Eligible students whose parents or guardians had provided consent were assembled in classrooms or designated private spaces within the school. Before completing the questionnaire, participants received a standardised explanation of the study purpose, procedures, voluntary nature of participation, confidentiality measures, and their right to decline or withdraw at any time without penalty. Data were collected using a structured, pre-tested questionnaire, primarily self-administered by participants. Research assistants were present to provide standardised instructions and clarify questions where necessary, but they did not guide or influence participants’ responses. To minimise peer influence and social desirability bias, students completed the questionnaires individually, with teachers absent during completion. Completed questionnaires were collected immediately, checked on-site for completeness, and stored securely. No personal identifiers were collected. Each questionnaire was assigned a unique study code, and all data were anonymised before analysis. Completed questionnaires were stored securely, and electronic data were entered into password-protected files accessible only to the research team. HPV vaccination status was primarily based on self-report. Participants were asked whether they had received at least one dose of the HPV vaccine. Where vaccination cards or school vaccination registers were available, reported vaccination status was checked against these records [33]. Because vaccination records were not systematically available for all participants, self-reported vaccination status was used as the primary measure in the analysis. This was considered when interpreting the findings. Data analysis Data were analysed using IBM SPSS Statistics for Windows, version 27 [34]. The dataset was first checked for completeness, consistency, missing values, and outliers. Descriptive statistics were used to summarise participants’ sociodemographic characteristics, knowledge, perceptions, HPV vaccination status, and willingness to receive the HPV vaccine. Categorical variables were presented as frequencies and percentages, while continuous variables were summarised using means and standard deviations. Composite knowledge and perception scores were generated as described above. Knowledge of cervical cancer, knowledge of HPV, knowledge of HPV vaccination, and perception of HPV vaccination were each categorised as poor or good using a 50% threshold. Scores below 50% were classified as poor, while scores of 50% or higher were classified as good. This threshold was applied consistently across the composite knowledge and perception domains. The two primary outcome variables were HPV vaccine uptake and willingness to receive the HPV vaccine in the future. HPV vaccine uptake was defined as self-reported receipt of at least one dose of the HPV vaccine. Willingness to receive the HPV vaccine was assessed only among participants who had not yet been vaccinated. For this outcome, participants who responded “Yes” were classified as willing, while those who responded “No” or “Maybe, I need more information” were classified as not currently willing, because “Maybe” reflected uncertain or conditional willingness rather than definite willingness. Bivariate associations between independent variables and each outcome were examined using chi-square tests. Crude odds ratios and 95% confidence intervals were estimated for each association. Variables were considered for inclusion in the multivariable models if they were statistically significant in bivariate analyses or were theoretically relevant based on prior evidence and the study objectives. These included age, class level, parental occupation, knowledge measures, perception of HPV vaccination, awareness of vaccine availability, and selected belief-related variables. Multivariable binary logistic regression models were fitted to identify factors associated with HPV vaccine uptake and willingness to receive the HPV vaccine. Binary logistic regression was used because both primary outcomes were dichotomous: vaccinated versus not vaccinated, and willing versus not currently willing to receive the vaccine. The strength of association was expressed as crude odds ratios and adjusted odds ratios with 95% confidence intervals. For the willingness analysis, only unvaccinated participants were included because willingness to receive the vaccine was assessed only among those who had not yet been vaccinated. Variables applicable only to unvaccinated participants, such as reasons for not receiving the HPV vaccine, were not included as predictors in the vaccine uptake model because these items were not measured among vaccinated participants. These variables were reported descriptively and, where appropriate, considered only in analyses restricted to unvaccinated participants. Multicollinearity among independent variables was assessed before fitting the final multivariable models using standard collinearity diagnostics. Variables with strong conceptual overlap were not entered simultaneously to reduce the risk of model instability. Model adequacy was assessed using standard diagnostic procedures, including the Hosmer–Lemeshow goodness-of-fit test. Statistical significance was set at p < 0.05. Because participants were recruited from selected schools, the possibility of intra-school correlation was considered when interpreting the findings. However, the final regression models were estimated using standard binary logistic regression in SPSS, and school-level clustering was not formally modelled using Complex Samples procedures or generalized estimating equations. This is acknowledged as a limitation of the analysis. Given the small number of participants who reported receiving the HPV vaccine, adjusted estimates from the vaccine uptake model were also interpreted cautiously, particularly where confidence intervals were wide. Ethical considerations Ethical approval for this study was obtained from the Oyo State Ministry of Health Ethics Review Committee (AD 13/479/894B) prior to the commencement of data collection. All procedures were conducted in accordance with the Declaration of Helsinki and applicable national research ethics guidelines. Because the study involved minors, written informed consent was obtained from parents or legal guardians, and assent was obtained from all participating students before enrollment. Participants and their caregivers were provided with clear information about the study’s purpose, the procedures involved, the voluntary nature of participation, and their right to decline or withdraw at any time without consequences. No incentives were offered for participation. To protect privacy and confidentiality, no personal identifiers were recorded on the questionnaires. Each participant was assigned a unique study code, and all data were stored in password-protected files accessible only to the research team. The findings are reported in aggregate form to prevent identification of individual participants or schools. Results Sociodemographic characteristics of study participants A total of 441 adolescent girls participated in the study. The mean age of participants was 12.74 ± 1.15 years. Most participants were aged 13 (34.9%), followed by 14 (26.5%) and 12 (20.9%). Although the study primarily targeted girls aged 9–14 years in line with Nigeria’s HPV vaccination target age group, seven participants aged 15–16 years were included because they were enrolled in the selected classes, had parental consent and student assent, and participated in the school-based data collection process. Overall, 98.4% of the sample fell within the intended age range of 9–14 years. By class level, the highest proportions of participants were in JSS2 and JSS3, with each class accounting for 25.6% of respondents. This was followed by JSS1 (22.9%) and SSS1 (20.2%). Regarding socioeconomic indicators, most participants reported receiving a daily allowance of ₦0–₦200 (68.5%), while 23.4% reported receiving ₦201–₦400. Parental occupation showed that 75.3% of parents or guardians were self-employed, 22.2% were salary earners, and 2.5% were unemployed. These characteristics are presented in Table 1. Table 1Sociodemographic characteristics of study participantsVariableFrequency (n = 441)n (%)Age (Mean ± SD)12.74 ± 1.15Age (years) 91 (0.2) 1013 (2.9) 1157 (12.9) 1292 (20.9) 13154 (34.9) 14117 (26.5) 155 (1.1) 162 (0.5)Religion Christianity240 (54.4) Islam199 (45.1) Traditional2 (0.5)Ethnicity Yoruba425 (96.4) Igbo9 (2.0) Hausa1 (0.2) Others6 (1.4)Class Basic25(5.7) JSS 1101 (22.9) JSS 2113 (25.6) JSS 3113 (25.6) SSS 189 (20.2)Estimated Daily Allowance (₦) 0-200302 (68.5) 201–400103 (23.4) 401–60025 (5.7) > 60011 (2.5)Parent’s Occupation Self Employed332(75.3) Salary earner98(22.2) Unemployed11 (2.5) Sociodemographic characteristics of study participants Knowledge of cervical cancer Overall awareness of cervical cancer was low among the participants. Of the 441 adolescent girls surveyed, only 115 girls (26.1%) reported that they had ever heard of cervical cancer, while 326 (73.9%) had not heard of it. Among the 115 participants who had heard of cervical cancer, schools were the most commonly reported source of information (57.4%), followed by friends or family members (20.0%), media outlets (13.0%), campaigns (6.1%), and other sources (3.5%). Among participants who had heard of cervical cancer, 45.2% correctly identified HPV as the primary cause of cervical cancer. Other participants attributed cervical cancer to HIV (20.0%), hereditary factors (3.5%), or unprotected sexual intercourse (7.8%), while 22.6% were unsure. Knowledge of early signs and symptoms was also limited among those aware of cervical cancer, with 37.4% reporting that they knew detectable early signs and symptoms, compared with 62.6% who did not. Similarly, 48.7% reported that cervical cancer is preventable, while 51.3% reported that it is not preventable. Based on the composite cervical cancer knowledge score among participants who had heard of cervical cancer, 88 of 115 participants (76.5%) were classified as having poor knowledge, while 27 (23.5%) were classified as having good knowledge. These findings are presented in Table 2; Fig. 1. Table 2Knowledge of Cervical CancerVariablesFrequency n (%)Have you ever heard of cervical cancer? Yes115 (26.1) No326 (73.9)Among those who have heard of CC If yes, where did you hear it from? School66 (57.4) Friend/Family23 (20.0) Media15 (13.0) Campaigns7 (6.1) Others4 (3.5)What do you think is the primary cause of cervical cancer? HPV (Human Papillomavirus)52 (45.2) HIV (Human Immunodeficiency Virus)23 (20.0) Hereditary factors4 (3.5) Unprotected sexual intercourse9 (7.8) Not sure26 (22.6)Do you know of any early signs and symptoms of cervical cancer that can be detected? Yes43 (37.4) No72 (62.6)Is cervical cancer preventable? Yes56 (48.7) No59 (51.3)At what age is it most appropriate to begin cervical cancer screening? Before puberty38 (33.0) After puberty but before 21 years30 (26.1) Between 21–29 years11 (9.6) After 30 years18 (15.7) Not sure18 (15.7)How often should a woman get screened for cervical cancer? Every year63 (54.8) Every 3 years15 (13.0) Every 5 years12 (10.4) Not sure25 (21.8)Does the use of tobacco products increase the risk of cervical cancer? Yes74 (64.3) No41 (35.7) Knowledge of Cervical Cancer Level of cervical cancer knowledge among participants who had heard of cervical cancer Knowledge of HPV Overall awareness of HPV was low among the participants. Of the 441 adolescent girls surveyed, only 127 (28.8%) reported having ever heard of HPV, while 314 (71.2%) had not. Among the 127 participants who had heard of HPV, schools were the most commonly reported source of information (58.3%), followed by family or friends (15.0%), healthcare providers (12.6%), the internet (4.7%), and other sources (9.4%). Among participants who had heard of HPV, knowledge of HPV-related health risks varied. Most identified cervical cancer as a potential health risk associated with HPV (59.1%), while fewer identified genital warts (8.7%) or other cancers such as throat or anal cancer (7.1%). Nearly one-quarter of those who had heard of HPV (24.2%) did not know any HPV-associated health risk. Knowledge of HPV transmission was also mixed: 62.2% identified sexual intercourse as a route of transmission, while fewer recognised oral sex (5.5%) or skin-to-skin genital contact (10.2%). Only 7.1% selected all listed transmission routes, and 15.0% reported not knowing how HPV is transmitted. Among those who had heard of HPV, 77.2% were aware that a vaccine exists to prevent HPV infection. However, knowledge of the recommended age for HPV vaccination was less consistent: 32.3% reported vaccination before puberty, 16.5% during puberty, and 24.4% did not know. Awareness of the role of HPV screening in early detection and prevention of cervical cancer was reported by 75.6% of participants who had heard of HPV. Across the full sample, interest in receiving more information about HPV was high, with 378 participants (85.7%) indicating that they would like to learn more about HPV and its prevention. Based on the composite HPV knowledge score among participants who had heard of HPV, 105 of 127 participants (82.7%) were classified as having good HPV knowledge, while 22 (17.3%) were classified as having poor knowledge. This finding should be interpreted in relation to the denominator and scoring threshold. Although overall HPV awareness in the full sample was low, knowledge was assessed among the smaller subgroup of participants who had already heard of HPV, and the classification was based on the pre-specified 50% cut-off. These findings are presented in Table 3; Fig. 2. Table 3Knowledge of HPVVariablesFrequencyn (%)Have you heard about Human Papillomavirus (HPV)? Yes127 (28.8) No314 (71.2)From where did you first learn about HPV? School74 (58.3) Internet6 (4.7) Family or friends19 (15.0) Healthcare provider16 (12.6) Other12 (9.4)Can you identify any potential health risks associated with HPV? Cervical cancer75 (59.1) Genital warts11 (8.7) Other types of cancer (e.g., throat or anal)9 (7.1) I don’t know32 (24.2)Do you know how HPV is transmitted? Sexual intercourse79 (62.2) Oral sex7 (5.5) Any skin-to-skin genital contact13 (10.2) All of the above9 (7.1) I don’t know19 (15.0)Are you aware that there is a vaccine to prevent HPV infection? Yes98 (77.2) No29 (22.8)If yes to the above, do you know at what age it is typically recommended to get the HPV vaccine? Before puberty41 (32.3) During puberty21 (16.5) After puberty10 (7.9) Anytime24 (18.9) I don’t know31 (24.4)Do you know that regular HPV screening can help in the early detection and prevention of cervical cancer? Yes96 (75.6) No31 (24.4)Would you be interested in learning more about HPV and how to prevent it? Yes378(85.7) No63 (14.3)Follow-up HPV knowledge questions were answered only by participants who reported having heard of HPV, unless otherwise stated. Interest in learning more about HPV was assessed among the full sample Knowledge of HPV Follow-up HPV knowledge questions were answered only by participants who reported having heard of HPV, unless otherwise stated. Interest in learning more about HPV was assessed among the full sample Level of HPV knowledge among participants who had heard of HPV Knowledge of HPV vaccination Overall awareness of HPV vaccination was low among the participants. Of the 441 adolescent girls surveyed, 128 (29.0%) reported that they had heard of the HPV vaccine, while 313 (71.0%) had never heard of it. Among the 128 participants who had heard of the HPV vaccine, knowledge of specific vaccine-related information varied. Fewer than one-fifth of participants who had heard of the vaccine correctly identified HPV types 16 and 18 as the HPV types most commonly prevented by HPV vaccination (18.8%), while 46.1% reported not knowing. However, knowledge of the recommended vaccination age was higher, with 77 participants (60.2%) correctly reporting that the first dose of the HPV vaccine should be given between the ages of 9 and 14. Regarding possible side effects, pain at the injection site was the most commonly identified response, reported by 54 participants (42.2%). In contrast, 35.2% did not know any possible side effects. A notable misconception was observed regarding post-vaccination protection. Among participants who had heard of the HPV vaccine, 95 (74.2%) reported that it is not possible to get HPV after vaccination. In comparison, only 33 (25.8%) recognised that HPV infection may still occur after vaccination. Based on the composite HPV vaccination knowledge score among participants who had heard of the vaccine, 66 of 128 participants (51.6%) were classified as having poor knowledge, and 62 (48.4%) as having good knowledge. These findings are presented in Table 4; Fig. 3. Table 4Knowledge of HPV vaccinationVariablesFrequencyn (%)Have you heard about HPV vaccine? Yes128 (29.0) No313 (71.0)Do you know the types of HPV most commonly prevented by the HPV vaccine? HPV 1 and 226 (20.3) HPV 6 and 1111 (8.6) HPV 16 and 1824 (18.8) All of the above8 (6.3) I don’t know59 (46.1)At what age is it recommended to get the first dose of the HPV vaccine? At birth15 (11.7) Between 9–14 years77 (60.2) Between 15–25 years9 (7.0) After 25 years6 (4.7) I don’t know21 (16.4)Are there any potential side effects of the HPV vaccine? Fever and nausea17 (13.3) Pain at the injection site54 (42.2) Headache10 (7.8) All of the above2 (1.6) I don’t know45 (35.2)Is it possible to get HPV even after getting vaccinated? Yes33 (25.8) No95 (74.2)Follow-up questions on HPV vaccination knowledge were answered only by participants who reported having heard of the HPV vaccine Knowledge of HPV vaccination Follow-up questions on HPV vaccination knowledge were answered only by participants who reported having heard of the HPV vaccine Level of HPV vaccination knowledge among participants who had heard of the HPV vaccine Perceptions and acceptance of HPV vaccination Perceptions and acceptance of HPV vaccination varied by vaccination status. Among the 400 participants who had not received the HPV vaccine, 156 (39.0%) reported willingness to receive the vaccine in the future, while 141 (35.2%) indicated they might consider vaccination if they received more information. The most commonly reported reason for non-vaccination was lack of information about HPV and the vaccine (49.3%), followed by low perceived risk of HPV infection (20.3%) and concerns about side effects (16.0%). Among the 41 participants who reported receiving the HPV vaccine, the most common motivation for vaccination was prevention of HPV-related diseases (48.8%), followed by a recommendation from a healthcare professional (19.5%). Compared with non-vaccinated participants, vaccinated participants more frequently reported that the HPV vaccine was necessary for preventing HPV-related diseases (63.4% versus 54.8%) and that the vaccine was either completely safe or mostly safe with minor side effects (70.8% versus 51.0%). In contrast, uncertainty about vaccine safety and effectiveness was more common among non-vaccinated participants: 46.5% were unsure about vaccine safety and 48.4% about vaccine effectiveness. Support for mandatory HPV vaccination was relatively low in both groups, with 41.5% of vaccinated participants and 35.2% of non-vaccinated participants reporting support. When asked about strategies to increase HPV vaccination among students, the most frequently suggested approach in both groups was providing more information about HPV and the HPV vaccine. This was reported by 68.3% of vaccinated participants and 67.5% of non-vaccinated participants. Based on the composite perception score, 228 of 400 non-vaccinated participants (57.0%) were classified as having a poor perception of HPV vaccination. Among vaccinated participants, 20 of 41 (48.8%) were classified as having poor perception, while 21 (51.2%) had good perception. These findings are presented in Table 5; Fig. 4. Table 5Perceptions and acceptance of HPV vaccination by vaccination statusVariablesVaccinated (n = 41)Non-vaccinated (n = 400)N (%)N (%)If you are not vaccinated, are you willing to get the HPV vaccine in the future? Yes-156 (39.0) No-103 (25.8) Maybe, I need more information.-141 (35.2)If you haven’t been vaccinated, what is the primary reason for not getting the HPV vaccine? I’m not at risk for HPV-81 (20.3) Concerns about side effects-64 (16.0) Lack of information-197 (49.3) Accessibility/cost issues-28 (7.0) Other-30 (7.4)If you have already received the HPV vaccine, what motivated you to get vaccinated? Prevention of HPV-related diseases20 (48.8)- Recommendation from a healthcare professional8 (19.5)- Peer/family influence2 (4.9)- Other11 (26.8)-Do you believe that the HPV vaccine is necessary for the prevention of HPV-related diseases? Yes26 (63.4)219 (54.8) No15 (36.6)181(45.2)What is your opinion on the safety of the HPV vaccine? It’s completely safe17 (41.5)150 (37.5) It’s mostly safe with minor side effects12 (29.3)54 (13.5) It has severe side effects1 (2.4)10 (2.5) I’m not sure about its safety11 (26.8)186 (46.5)How do you perceive the effectiveness of the HPV vaccine in preventing HPV-related diseases? Very effective19 (46.3)131 (32.8) Somewhat effective5 (12.2)42 (10.5) Not effective3 (7.3)33 (8.3) I’m not sure about its effectiveness14 (34.1)194 (48.4)Do you think that the HPV vaccine should be mandatory for all eligible individuals? Yes17 (41.5)140 (35.2) No24 (58.5)260 (64.8)If the HPV vaccine were made readily available and affordable to you, would you be willing to get vaccinated? Yes20 (48.8)204 (51.0) No12 (29.3)89 (22.3) Maybe9 (22.0)106 (26.7) Missing/not stated-1 (0.2)What do you think can be done to increase HPV vaccination rates among students like yourself? More information about HPV and the vaccine28 (68.3)270 (67.5) Make the vaccine more accessible7 (17.1)82 (20.5) Lower the cost of the vaccine3 (7.3)22(5.5) Other3 (7.3)25(6.5) Missing/not stated-1 (0.2)Percentages were calculated within vaccination-status groups unless otherwise indicated. Questions on willingness to receive the HPV vaccine and reasons for non-vaccination were asked only among non-vaccinated participants. The question about vaccination motivation was asked only among vaccinated participants. For regression analysis, willingness to receive the HPV vaccine was dichotomised as “Yes” versus “No/Maybe,” with “Maybe” treated as an indicator of uncertain or conditional willingness Perceptions and acceptance of HPV vaccination by vaccination status Percentages were calculated within vaccination-status groups unless otherwise indicated. Questions on willingness to receive the HPV vaccine and reasons for non-vaccination were asked only among non-vaccinated participants. The question about vaccination motivation was asked only among vaccinated participants. For regression analysis, willingness to receive the HPV vaccine was dichotomised as “Yes” versus “No/Maybe,” with “Maybe” treated as an indicator of uncertain or conditional willingness Perception of HPV Vaccination by vaccination status Factors associated with HPV vaccine uptake Table 6 presents the bivariate and multivariable logistic regression analyses of factors associated with self-reported HPV vaccine uptake among participants. HPV vaccine uptake was defined as receipt of at least one dose of the HPV vaccine. Table 6Factors associated with self-reported HPV vaccine uptakeVariableCategoriesCrude OR (95% CI)P-valueAdjusted OR95% CIP-valueAge (years)≤10RefRef110.453 (0.074–2.765)0.3910.657 (0.083–5.188)0.690120.345 (0.060–1.979)0.2320.274 (0.035–2.131)0.216130.417 (0.082–2.123)0.2920.815 (0.109–6.122)0.843≥141.154 (0.240–5.555)0.8582.293 (0.301–17.482)0.423ClassBasicRefRefJSS 10.094 (0.012–1.747)0.4830.359 (0.087–1.491)0.159JSS 20.400 (0.110–1.451)0.1630.227 (0.049–1.053)0.058JSS 30.804 (0.242–2.666)0.7210.192 (0.041–0.908)0.037*SS 10.183 (0.038–0.881)0.034**0.063 (0.009–0.433)0.005*Parent/guardian occupationUnemployedRefRefSelf-employed0.564(0.117–2.712)0.4750.585 (0.092–3.709)0.569Salary earner0.094(0.012–0.747)0.025**0.104 (0.010–1.056)0.056Knowledge of cervical cancerPoor knowledgeRefRefGood knowledge2.350(1.157–4.773)0.018**2.451 (0.951–6.320)0.063Knowledge of HPVPoor knowledgeRefRefGood knowledge1.021(0.537–1.943)0.9480.422 (0.152–1.168)0.097Knowledge of HPV vaccinationPoor knowledgeRefRefGood knowledge0.860(0.383–1.928)0.7130.485 (0.180–1.305)0.152Perception of HPV vaccinePoor perceptionRefRefGood perception3.876(2.011–7.474)< 0.001*11.000 (3.532–34.253)< 0.001*Awareness that there is a vaccine to prevent HPV infectionNoRefRefYes1.442(0.747–2.783)0.2751.316 (0.534–3.246)0.551Interest in learning more about HPV and how to prevent it?NoRefRefYes0.555(0.251–1.227)0.1460.677 (0.243–1.890)0.456Belief that HPV vaccine should be mandatory for eligible individualsNoRefRefYes0.760 (0.395–1.463)0.4121.890 (0.712–5.017)0.201Outcome variable: self−reported receipt of at least one dose of HPV vaccineOR odds ratio, AOR adjusted odds ratio, CI confidence interval, Ref reference category*− statistically significant*Statistically significant at p < 0.05. Reasons for non−vaccination were excluded from this model because they were assessed only among participants who had not received the HPV vaccine Factors associated with self-reported HPV vaccine uptake Outcome variable: self−reported receipt of at least one dose of HPV vaccine OR odds ratio, AOR adjusted odds ratio, CI confidence interval, Ref reference category *− statistically significant *Statistically significant at p < 0.05. Reasons for non−vaccination were excluded from this model because they were assessed only among participants who had not received the HPV vaccine In the adjusted model, class level and perception of the HPV vaccine were significantly associated with HPV vaccine uptake. Compared with participants in Basic classes, those in JSS3 were less likely to report HPV vaccination uptake (AOR = 0.19; 95% CI: 0.04–0.91; p = 0.037), while those in SS1 also had lower odds of vaccination uptake (AOR = 0.06; 95% CI: 0.01–0.43; p = 0.005). Participants with a positive perception of the HPV vaccine had substantially higher odds of vaccination than those with a negative perception (AOR = 11.00; 95% CI: 3.53–34.25; p < 0.001). Knowledge of cervical cancer showed a positive association in the bivariate analysis but did not remain statistically significant after adjustment (AOR = 2.45; 95% CI: 0.95–6.32; p = 0.063). Knowledge of HPV, knowledge of HPV vaccination, awareness that a vaccine exists to prevent HPV infection, and interest in learning more about HPV were not independently associated with vaccine uptake after adjustment. Variables applicable only to non-vaccinated participants, such as reasons for not receiving the HPV vaccine, were not included in the vaccine uptake regression model because they were not measured among vaccinated participants. These variables are therefore reported descriptively in Table 5. Given the small number of participants who reported vaccination, the adjusted estimates should be interpreted cautiously, particularly when confidence intervals are wide. Factors associated with willingness to receive the HPV vaccine in the future Table 7 presents factors associated with willingness to receive the HPV vaccine among participants who had not yet been vaccinated. This analysis was restricted to the 400 non-vaccinated participants because the willingness question was asked only among those who had not received the HPV vaccine. For this analysis, participants who responded “Yes” were classified as willing to receive the vaccine. In contrast, those who responded “No” or “Maybe, I need more information” were classified as not currently willing. Table 7Factors associated with willingness to receive the HPV vaccine among non-vaccinated participantsVariableCategoriesCrude OR (95% CI)P-valueAdjusted OR 95% CIP-valueAge (years)≤10RefRef110.349 (0.103–1.179)0.0900.401 (0.092–1.752)0.224120.391 (0.121–1.259)0.1150.379 (0.085–1.680)0.201130.345 (0.110–1.079)0.0670.316 (0.071–1.398)0.129≥140.295 (0.093–0.935)0.038*0.290 (0.063–1.342)0.113ClassBasicRefRefJSS 11.255 (0.515–3.058)0.6181.798 (0.604–5.349)0.292JSS 20.791 (0.325–1.924)0.6041.187 (0.392–3.593)0.761JSS 31.582 (0.655–3.818)0.3082.896 (0.915–9.167)0.071SS 10.380 (0.147–0.986)0.047*1.384 (0.390–4.916)0.615Parent occupationUnemployedRefRefSelf-employed6.517 (0.825–51.514)0.0765.985 (0.570-62.881)0.136Wage-earner6.610 (0.813–53.713)0.0776.441 (0.593–70.004)0.126Knowledge of cervical cancerPoor knowledgeRefRefGood knowledge1.499 (0.918–2.448)0.1060.628 (0.324–1.214)0.166Knowledge of HPVPoor knowledgeRefRefGood knowledge2.806 (1.887–4.172)< 0.001*1.206 (0.643–2.261)0.559Knowledge of HPV vaccinationPoor knowledgeRefRefGood knowledge1.805 (1.143–2.850)< 0.001*0.721 (0.394–1.320)0.289Perception of HPV vaccinePoor perceptionRefRefGood perception9.321 (5.665–15.337)< 0.001*6.243 (3.160-12.332)< 0.001*Awareness that there is a vaccine to prevent HPV infection?NoRefRefYes3.132 (2.088–4.698)< 0.001*1.676 (0.943–2.980)0.078Are you interested in learning more about HPV and how to prevent it?NoRefRefYes1.558 (0.876–2.771)0.1321.027 (0.512–2.062)0.940Reasons for not being vaccinatedI’m not at risk for HPV0.845 (0.459–1.554)0.5870.967 (0.377–2.480)0.944Concerns about side effects0.523 (0.315–0.867)0.0121.161 (0.451–2.991)0.757Lack of information0.772 (0.331–1.799)0.5480.853 (0.361–2.018)0.717Accessibility/cost issues0.745 (0.343–1.619)0.4581.084 (0.343–3.421)0.891OthersRefRefDo you think the HPV vaccine should be mandatory for all eligible individuals?NoRefRefYes3.224 (2.146–4.843)< 0.001*1.082 (0.601–1.949)0.793If vaccines were made availableNoRefRefYes2.245 (1.391–3.625)< 0.001*2.567 (1.537–4.288)< 0.001**− statistically significantThe availability/affordability item reflects conditional access−related willingness and was interpreted cautiously because it overlaps conceptually with the willingness outcome Factors associated with willingness to receive the HPV vaccine among non-vaccinated participants *− statistically significant The availability/affordability item reflects conditional access−related willingness and was interpreted cautiously because it overlaps conceptually with the willingness outcome In the adjusted model, perception of the HPV vaccine remained the strongest factor associated with willingness to be vaccinated. Participants with a positive perception of the HPV vaccine had higher odds of being willing to receive it than those with a negative perception (AOR = 6.24; 95% CI: 3.16–12.33; p < 0.001). Willingness was also significantly higher among participants who indicated that they would receive the vaccine if it were made readily available and affordable (AOR = 2.57; 95% CI: 1.54–4.29; p < 0.001). Although good knowledge of HPV, good knowledge of HPV vaccination, awareness that a vaccine exists, and support for mandatory vaccination showed significant associations in the crude analyses, these associations were no longer statistically significant after adjustment. Age, class level, parental occupation, interest in learning more about HPV, and reasons for non-vaccination were also not independently associated with willingness to receive the HPV vaccine after adjustment. These findings suggest that favourable vaccine perceptions and perceived access were more strongly associated with willingness than factual knowledge alone. Belief-related factors associated with willingness to receive the HPV vaccine in the future Table 8 presents belief-related factors associated with willingness to receive the HPV vaccine among participants who had not yet been vaccinated. This analysis was restricted to unvaccinated participants because the willingness outcome was assessed only among those who had not received the HPV vaccine. Participants who believed that the vaccine was necessary (AOR = 2.51; 95% CI: 1.56–4.06; p < 0.001) and effective (AOR = 3.21; 95% CI: 2.04–5.05; p < 0.001) had higher odds of willingness to be vaccinated. Belief that regular HPV screening helps in early detection and prevention of cervical cancer was also associated with willingness (AOR = 2.62; 95% CI: 1.61–4.26; p < 0.001). Participants who believed that HPV infection can still occur after vaccination had lower odds of willingness to be vaccinated (AOR = 0.30; 95% CI: 0.17–0.55; p < 0.001). This finding may reflect uncertainty about vaccine protection and should be interpreted cautiously. Table 8Belief-related factors associated with willingness to receive the HPV vaccine among non-vaccinated participantsVariableCategoriesCrude OR (95% CI)P-valueAdjusted OR 95% CIP-valueIs the HPV vaccine necessary for the prevention of HPV-related diseases?NoRefRefYes3.397 (2.244–5.142)< 0.001*2.512 (1.555–4.059)< 0.001*Is the HPV vaccine effective in preventing HPV-related diseases?NoRefRefYes3.889 (2.567–5.891)< 0.001*3.212 (2.040–5.050)< 0.001*Is it possible to get HPV even after getting vaccinated?NoRefRefYes0.564 (0.330–0.964)0.036*0.304 (0.167–0.552)< 0.001*Does regular HPV screening help in the early detection and prevention of cervical cancer?NoRefRefYes3.941 (2.55–6.074)< 0.001*2.618 (1.610–4.258)< 0.001**− statistically significant Belief-related factors associated with willingness to receive the HPV vaccine among non-vaccinated participants *− statistically significant Discussion This study assessed HPV vaccine awareness, knowledge, perceptions, self-reported uptake, and willingness among in-school adolescent girls in rural Oyo State during Nigeria’s national HPV vaccine rollout [11]. Overall awareness of cervical cancer, HPV, and HPV vaccination was low in the full sample, while self-reported HPV vaccine uptake was also low. Among participants who had previously heard of HPV, the proportion classified as having good HPV knowledge was higher; however, this should be interpreted with caution because the denominator was restricted to those already aware of HPV and the classification used a pre-specified 50% threshold. In the adjusted analyses, favourable perception of the HPV vaccine, particularly beliefs about safety, necessity, and effectiveness, was consistently associated with both self-reported uptake and willingness to receive the vaccine. Given the cross-sectional design and the small, vaccinated subgroup, these findings should be interpreted as associations rather than causal effects [35–39]. The low levels of awareness observed in this study align with previous Nigerian reports among in-school adolescents and women, where knowledge of HPV and HPV vaccination has often been limited [40, 41]. Similar patterns have been reported in other sub-Saharan African settings, including Uganda and pooled regional analyses, which document gaps in HPV-related awareness and vaccine uptake among adolescent girls [35, 42]. A systematic review across sub-Saharan Africa also reported low HPV vaccine uptake and highlighted the importance of knowledge and other psychosocial factors in vaccination behaviour [38]. In contrast, studies among more educated groups, such as tertiary institution students and healthcare workers, have reported higher awareness levels [43–47]. The present findings therefore add implementation-relevant evidence from a rural school-based population during active national rollout. Favourable perception of the HPV vaccine was strongly associated with self-reported vaccine uptake in the multivariable model. This finding suggests that vaccine confidence, perceived safety, perceived necessity, and perceived effectiveness may be important correlates of HPV vaccine acceptance in this setting [48, 49]. However, the large, adjusted odds ratio should be interpreted cautiously because only 41 participants reported receiving the vaccine, resulting in a relatively small, vaccinated subgroup. Prior studies in Nigeria and other settings have shown that concerns about side effects, fertility, and long-term safety can affect HPV vaccine confidence [50, 51]. In the present study, uncertainty about vaccine safety and effectiveness was more common among non-vaccinated participants. Although the sources of this uncertainty cannot be determined from the present data, this finding suggests the need for communication strategies that address not only factual knowledge but also vaccine-related concerns and perceptions [52]. These findings may therefore support the value of clear, age-appropriate HPV vaccination communication that addresses knowledge gaps, perceived safety, perceived effectiveness, and trust in the vaccine [18, 48]. Caregiver attitudes, parental decision-making, and misinformation exposure were not directly measured in this study; therefore, they are discussed here as background context from previous literature rather than as empirical findings from the present dataset. This distinction is important because adolescent vaccination often occurs within family decision-making structures, where parental or guardian consent is commonly required for girls aged 9–14 years [51, 53–55]. In the present study, schools were frequently reported as sources of HPV-related information, suggesting that school-based platforms may serve as important channels for communicating HPV vaccine information to adolescents and, indirectly, to families. Similar patterns have been reported across LMICs, where caregiver beliefs, safety concerns, and trust in institutions have been associated with HPV vaccine acceptance for adolescent girls [56, 57]. Previous research has also documented low caregiver knowledge and misinformation-related concerns as barriers to HPV vaccination in some settings [51, 55, 58]. However, because caregiver knowledge, attitudes, parental approval, and misinformation exposure were not directly assessed in the present study, these factors cannot be used to explain the observed uptake patterns. Future studies should include caregivers, teachers, and health workers to better understand how household, school, and health-system factors may interact with adolescent perceptions to influence HPV vaccine uptake. The prominence of schools as the primary source of information on both cervical cancer and HPV suggests that school-based platforms may be important channels for HPV vaccine communication in rural communities. Beyond their role in vaccine delivery, schools may provide structured spaces where adolescents can receive age-appropriate health information from familiar and credible sources. This interpretation is consistent with intervention studies in Nigeria, including educational programmes among in-school adolescents in Ibadan that improved HPV knowledge, perceptions, and intention to vaccinate [30, 59]. In the present study, the frequent reporting of schools as information sources suggests that sustained engagement of teachers and school administrators could strengthen HPV vaccine communication and support informed decision-making among students and families [60, 61]. However, the study did not directly assess the quality, content, or influence of school-based communication. Given the increasing circulation of unverified health information, including through social media, vaccination programmes may need to provide clear, scientifically accurate messages that address common concerns and misconceptions [18]. These findings suggest the potential value of integrating foundational HPV education with school-based vaccine delivery during the national rollout. The finding that some unvaccinated girls reported that they were not at risk for HPV infection suggests that low perceived susceptibility may be relevant to vaccine willingness. Low perceived risk has been described in previous literature as a barrier to preventive health behaviour and may be influenced by limited sexual health education or social norms that discourage open discussion of sexual and reproductive health [62]. In the context of HPV, where infection is sexually transmitted and often asymptomatic, adolescents and families may underestimate the relevance of vaccination before exposure [63]. However, this study cannot determine the reasons for low perceived risk. Communication strategies may therefore benefit from framing HPV vaccination primarily as cancer prevention while clearly explaining the rationale for vaccinating girls aged 9–14 years. Overall, the findings suggest that the early phase of HPV vaccination implementation in rural school settings may benefit from combining vaccine availability with clearer communication, adolescent-appropriate education, and engagement with school and family contexts [9, 64]. The data do not directly demonstrate misinformation exposure, caregiver hesitancy, parental influence, or a trust deficit. Rather, they show measurable gaps in awareness, vaccine-related perceptions, perceived risk, and information needs. Addressing these areas through school-based and community-linked communication may support more equitable HPV vaccine uptake in rural and hard-to-reach settings [64, 65]. Conclusion This study found low overall awareness of cervical cancer, HPV, and HPV vaccination among in-school adolescent girls in rural Oyo State during Nigeria’s HPV vaccine rollout. Self-reported HPV vaccine uptake was also low, while a proportion of unvaccinated girls expressed definite willingness to receive the vaccine in the future. Favourable perception of the HPV vaccine, particularly beliefs about its safety, necessity, and effectiveness, was consistently associated with self-reported uptake and willingness to be vaccinated. Schools were the most commonly reported source of HPV-related information among girls who had heard of cervical cancer or HPV, suggesting that school-based platforms may be useful for strengthening vaccine communication. These findings support the need for clear, age-appropriate HPV vaccine education, communication around vaccine safety and benefits, and careful engagement with parents or guardians as part of school- and community-based vaccination strategies. Limitations This study has some limitations. First, the cross-sectional design limits causal inference; therefore, observed associations between knowledge, perceptions, and HPV vaccination outcomes should not be interpreted as causal relationships. Second, HPV vaccination status was primarily self-reported, with verification from vaccination cards or school records only where available, which may have introduced recall or misclassification bias. Third, only 41 participants reported receiving the HPV vaccine, and estimates from the uptake model, particularly those with wide confidence intervals, should be interpreted cautiously. Fourth, the study was conducted among in-school adolescent girls in selected rural LGAs of Oyo State, which may limit generalisability to out-of-school girls, adolescents in urban settings, and other Nigerian contexts. Although the intended eligibility range was 9–14 years, a small number of older students aged 15–16 years enrolled in selected classes were retained in the analysis. In addition, caregiver knowledge, attitudes, decision-making, access-related barriers, and misinformation exposure were not directly or comprehensively measured; therefore, interpretations related to caregiver influence, access, or misinformation should be considered indirect. Finally, although a design effect was incorporated in the sample size calculation, the regression models were fitted using standard binary logistic regression in SPSS rather than a dedicated complex samples or GEE procedure; potential residual intra-school correlation may therefore have affected the precision of some estimates. Recommendation Nigeria’s HPV vaccination programme may benefit from strengthening communication and trust-building activities alongside vaccine delivery, particularly in rural school settings. School-based HPV education should provide clear, age-appropriate information on HPV, cervical cancer prevention, vaccine safety, vaccine effectiveness, and the rationale for vaccinating girls aged 9–14 years. Teachers and school health personnel could be supported with standardised communication materials to ensure that students receive consistent and accurate information. Because adolescent vaccination commonly involves parent or guardian consent, caregiver-focused communication should also be considered as part of school-based vaccination activities. This may include parent-teacher meetings, community dialogues, consent-form information sheets, and culturally appropriate materials addressing common concerns about side effects, fertility, vaccine safety, and the preventive purpose of HPV vaccination. Routine monitoring of questions, concerns, and misinformation during rollout may also help vaccination teams adapt communication strategies to local needs, especially in rural and underserved communities. Supplementary Information Supplementary Material 1: Supplementary File 1: Study Survey Tools. Acknowledgements The authors sincerely thank the Oyo State Ministry of Health and the Oyo State Ministry of Education for granting permission to conduct this study. We are also grateful to the school administrators, teachers, and students in the participating schools for their cooperation and support throughout the data collection process. We acknowledge the valuable contributions of the research assistants who supported field implementation and data collection. We also appreciate the parents and guardians who consented to their children’s participation in this study. Their willingness and trust made this research possible. Abbreviations Human papillomavirus Knowledge, attitudes, and perceptions Local government areas National bureau of statistics World health organisation Authors’ contributions IEA, FTA, ORA, and OCE conceptualised the study; IEA, FTA, ORA, OMO, and MTO led data collection; and IEA, FTA, ORA, GMA, ANC, and PEA drafted the initial manuscript. ORA, FTA, DOR, MTO, and LOE contributed to data analysis and interpretation. All authors reviewed and edited manuscript drafts for intellectual content. All authors reviewed and approved the final version of the manuscript. Funding This study was supported by a grant from the Royal Society of Tropical Medicine and Hygiene (RSTMH) Small Grants Programme. The funder had no role in the study design, data collection, data analysis, interpretation of results, or the writing of this manuscript. Data availability The datasets generated and/or analysed during the current study are available from the corresponding author upon reasonable request. Declarations Ethics approval and consent to participate Ethical approval for this study was obtained from the Oyo State Ministry of Health Research Ethics Committee (AD 13/479/894B). The study was conducted in full accordance with the ethical principles outlined in the Declaration of Helsinki for research involving human participants. All participants received detailed information about the study in English and Yoruba to ensure full understanding. Written informed consent was obtained from all participants prior to participation. Participants were informed of their right to decline or withdraw from the study at any time without penalty. Consent for publication Not Applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Ifeoluwa Eunice Adewole and Folahanmi Tomiwa Akinsolu contributed equally to this work. References Associated Data Supplementary Materials Supplementary Material 1: Supplementary File 1: Study Survey Tools. Data Availability Statement The datasets generated and/or analysed during the current study are available from the corresponding author upon reasonable request.